Flagship explainer
What drives Niagen Bioscience, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $17.4M | FY2025 |
| |
| Income before tax | $18.2M | FY2025 |
|
| Operating income | $16.3M | FY2025 |
|
| $129M | FY2025 |
| |
| Ending assets | $106M | FY2025 |
|
| Beginning assets | $68.3M | FY2024 |
|
| $76.5M | FY2025 |
| |
| $46.1M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001386570-26-000013
- SEC filingFiling detailsAccession 0001628280-25-009774